About this trial

This study compares the safety and efficacy of three endoscopic enucleation techniques for large prostates (\>100 mL) in patients with benign prostatic hyperplasia (BPH): Thulium Fiber Laser Enucleation (ThuFLEP), Holmium Laser Enucleation (HoLEP), and Bipolar Enucleation (B-TUEP). Ninety male patients with severe lower urinary tract symptoms (IPSS ≥20, Qmax ≤10 mL/s) who failed medical therapy will be randomized 1:1:1 into three groups of 30. Primary outcomes include IPSS, quality of life score, maximum flow rate (Qmax), and post-void residual at 1, 3, and 6 months postoperatively. Secondary outcomes include operative time, enucleation efficiency, blood loss, catheterization duration, hospital stay, and complication rates assessed by the Clavien-Dindo classification.

Eligibility criteria

Qualifiers

Male patients diagnosed with BPH

Clinical diagnosis of BPH with lower urinary tract symptoms.

IPSS ≥ 20 (severe symptoms)

Maximum urinary flow rate (Qmax) ≤ 10 mL/s

Disqualifiers

Prostate cancer (current or history).

Previous prostate surgery

Previous urethral surgery.

Neurogenic bladder dysfunction.

Trial design

Treatments tested in this trial

  • Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP)
  • Holmium Laser Enucleation of the Prostate (HoLEP)
  • Bipolar Transurethral Enucleation of the Prostate (B-TUEP)

Treatment groups

90 Participants
are divided into 3 treatment groups

Locations

1
Tanta University Hospital31111, TantaGharbia Governorate, Egypt

Sponsors and collaborators

Tanta University

Lead sponsor